Clinical Trial Update: Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating once-daily lonafarnib with ritonavir for chronic hepatitis D virus infection is ongoing, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• Lonafarnib (lonafarnib)
• Ritonavir (Ritonavir)

Snippet

Sponsor: Soroka University Medical Center | Conditions: Hepatitis D, Chronic | Phase 3 | Status: UNKNOWN